Modern Phytotherapy in Patients with Benign Prostate Hyperplasia and Chronic Prostatitis
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Treatment of prostate diseases remains one of the priorities in modern medicine. The patients with chronic inflammation and benign prostate hyperplasia (BPH) have a larger volume of the gland, more pronounced clinical manifestations of the disease and a higher probability of acute urinary retention development.
The choice of the medication treatment of BPH and chronic prostatitis (CP) is under the influence of many factors, namely: the nature of clinical manifestations of the disease, the volume of adenomatous tissue, the severity and features of urinary disorders and disorders of the functional state of the bladder.
Plant medications are very popular in many countries of the world, primarily due to the minimal severity of side effects.
The objective: to analyze the efficacy and tolerability of dietary supplements in the treatment of patients with BPH and CP.
Materials and methods. 90 patients with BPH stage I-II were involved in the study, the average age and the duration of the disease were practically similar. Patients were divided into two groups depending on the treatment. The main group included 56 men who received a medication produced by company “BEHEALTH” for condition improvement of CP and BPH. This drug includes all the components listed in the “Phytotherapy” section of Recommendations of the Treatment of the European Association of Urology (2019). The comparison group included 34 patients who received a monocomponent medication.
The tolerance of the product in patients of the main group was evaluated on the basis of subjective sensations and objective data during the treatment.
Results. After the treatment the patients in both groups had an improvement in the clinical condition, taking into account the main complaints (intermittent and weakening of a jet of urine, feeling of incomplete emptying of the bladder, polakiuria, imperative urges). After 3 months of treatment in the main group the maximum rate of urination increased significantly, dysuria symptoms decreased.
In 7 patients of the main group (30±10%) with the output volume of up to 80 ml and the volume of residual urine up to 150 ml after the treatment, the largest and significant decrease in the volume of residual urine on average up to 40±6 ml (p<0.05) was established. QOL decreased by 9.13 % (p>0.05), prostate volume – by 13.3 % (p>0.05), maximum and average urination rate increased (9.1 % and 14.6 % respectively; p>0.05).
Treatment has ensured effective elimination of symptoms of lower urinary tract caused by BPH, which is confirmed by clinical improvement in 94.1 % of patients in the main group.
Conclusions. As a result of the study, the effectiveness of the medication produced by company “BEHEALTH” for condition improvement by CP and BPH in the treatment of patients with benign prostate hyperplasia (BPH) and chronic prostatitis (CP) both objective and subjective indicators was determined (IPSS and QOL).
Phytotherapy has demonstrated its high efficiency and safety in the treatment of BPH, in particular in relieving the symptoms of CP, preventing the progression of the disease, improving the patient’s quality of life and the minimum level of side effects, which allows it to be used for a long time.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, Abrams P. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol. 1994;74(1):50–6. doi: 10.1111/j.1464-410x.1994.tb16546.x.
Bales GT, Christiano AP, Kirsh EJ, Gerber GS. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urol. 1999;54(1):86–9. doi: 10.1016/s0090-4295(99)00028-x.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9. doi: 10.1016/s0022-5347(17)49698-4.
Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48(3):398–405. doi: 10.1016/s0090-4295(96)00353-6.
Engelmann U, Walther C, Bondarenko B, Funk P, Schlafke S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222–9. doi: 10.1055/s-0031-1296714.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91. doi: 10.1056/NEJM199210223271701.
Lukacs B, Grange JC, Comet D, McCarthy C. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol. 2000;37(2):183–90. doi: 10.1159/000020116.
Lepor, H. For the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 1998;160:1358–67.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. doi: 10.1056/NEJMoa030656.
Paubert-Braquet M, Cave A, Hocquemiller R, Delacroix D, Dupont C, Hedef N, et al. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat Cell Signal. 1994;9(3):285–90.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63. doi: 10.1056/NEJM199802263380901.
Yablonsky F, Nicolas V, Riffaud JP, Bellamy F. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol. 1997;157(6):2381–7. Erratum in: J Urol 1997 Sep;158(3 Pt 1):889.
Wilt TJ, MacDonald R, Ishani A. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 199;83(9):976–83. doi: 10.1046/j.1464-410x.1999.00026.x.
Serenoa repens for benign prostatic hyperplasia. James Tacklind, Roderick MacDonald, Indy Rutks, and Timothy J Wilt2.
Abbott, K.C., et al. Hospitalized nephrolithiasis aft er renal transplantation in the United States. Am J Transplant, 2003. 3: 465.
Serenoa repens and its effects on male sexual function. A systematic review and meta-analysis of clinical trials. Gianni Paulis, Andrea Paulis, Gianpaolo Perletti.
A Review of the Potential of Phytochemicals from Prunus africana (Hook f.) Kalkman Stem Bark for Chemoprevention and Chemotherapy of Prostate Cancer. Richard Komakech, Youngmin Kang, Jun-Hwan Lee, and Francis Omujal.
Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosterol glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol 1986; 12: 187–9.
Chang RT, Kirby R, Challacombe BJ. Is there a link between BPH and prostate cancer? Practitioner. 2012 Apr;256(1750):13-6, 2.
